Publications

Maintenance Capecitabine and Bevacizumab Versus Bevacizumab Alone After Initial First-Line Bevacizumab and Docetaxel for Patients with Her2-Negative Metastatic Breast Cancer (Imelda): a Randomised, Open-Label, Phase 3 Trial

AuthID
P-009-YVB

Author(s)

Gligorov, J

Doval, D

Bines, J

Alba, E

Cortes, P

Pierga, JY

Gupta, V

Costa, R

Srock, S

de Ducla, S

Freudensprung, U

Mustacchi, G

Document Type

Article

Year published

2014

Published

in LANCET ONCOLOGY, ISSN: 1470-2045

Volume: 15, Issue: 12, Pages: 1351-1360 (10)

Indexing

Wos^®

Scopus^®

Crossref^®

Google Scholar^®

Publication Identifiers

DOI: 10.1016/s1470-2045(14)70444-9

Scopus: 2-s2.0-84908229537

Wos: WOS:000344546400046

Source Identifiers

ISSN: 1470-2045

Export Publication Metadata

Marked List

Add to Marked List

Citations

Oops! It looks like you don't have access to this content.

This section is restricted to uses with b-on access.

CORE Conference

No information about CORE Rank

During the preprocessing phase, only publications of type 'Proceedings Paper' or 'Proceedings' are automatically processed to identify their CORE Rank.

TIP: If your publication's CORE Rank is missing, you can contact with your institutional manager to have the correct ranking manually added to the record.

Journal Factors

Oops! It looks like you don't have access to this content.

This section is restricted to uses with b-on access.

Full Text

Full Text @ sfx.b-on.pt

Maintenance Capecitabine and Bevacizumab Versus Bevacizumab Alone After Initial First-Line Bevacizumab and Docetaxel for Patients with Her2-Negative Metastatic Breast Cancer (Imelda): a Randomised, Open-Label, Phase 3 Trial

Useful Links

Get Help

Federated Authentication (Click on the image)

Maintenance Capecitabine and Bevacizumab Versus Bevacizumab Alone After Initial First-Line Bevacizumab and Docetaxel for Patients with Her2-Negative Metastatic Breast Cancer (Imelda): a Randomised, Open-Label, Phase 3 Trial

Useful Links

Get Help